Cancer drug sorafenib could help save Insulin-Making cells in new diabetes patients
NCT ID NCT06227221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the cancer drug sorafenib can help people newly diagnosed with type 1 diabetes keep making their own insulin. Ten adults aged 18-60 will receive either sorafenib or a placebo daily, along with their usual insulin. The study measures changes in insulin production over time to see if the drug slows the loss of beta cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sorafenib (a cancer drug) taken as a daily pill
What this could lead to
If it works, this could point toward a way to preserve the body's own insulin production in people newly diagnosed with type 1 diabetes, potentially reducing the amount of insulin they need.
What could go wrong
This is a very small, early-phase trial with only 10 people, so results may not apply broadly. Sorafenib is a cancer drug with known side effects, and it is not yet clear if it will help diabetes or cause harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.